Free Trial

Trading of Apollomics was halted at 02:17 PM EST due to "LULD pause".

NASDAQ:APLM

Apollomics (APLM) Stock Price, News & Analysis

Apollomics logo
$7.08 -0.18 (-2.48%)
Closing price 03:59 PM Eastern
Extended Trading
$6.96 -0.13 (-1.77%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Apollomics Stock (NASDAQ:APLM)

Key Stats

Today's Range
$6.30
$7.39
50-Day Range
$4.63
$10.39
52-Week Range
$4.47
$36.75
Volume
11,200 shs
Average Volume
99,059 shs
Market Capitalization
$7.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Apollomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
8th Percentile Overall Score

APLM MarketRank™: 

Apollomics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Apollomics.

  • Price to Book Value per Share Ratio

    Apollomics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.17% of the float of Apollomics has been sold short.
  • Short Interest Ratio / Days to Cover

    Apollomics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Apollomics has recently decreased by 25.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Apollomics does not currently pay a dividend.

  • Dividend Growth

    Apollomics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.17% of the float of Apollomics has been sold short.
  • Short Interest Ratio / Days to Cover

    Apollomics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Apollomics has recently decreased by 25.78%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Apollomics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Apollomics insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 19.13% of the stock of Apollomics is held by institutions.

  • Read more about Apollomics' insider trading history.
Receive APLM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter.

APLM Stock News Headlines

This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
Biotech fails trials for its leukemia drug
See More Headlines

APLM Stock Analysis - Frequently Asked Questions

Apollomics' stock was trading at $9.75 at the beginning of the year. Since then, APLM stock has decreased by 27.4% and is now trading at $7.08.
View the best growth stocks for 2025 here
.

Shares of Apollomics reverse split on the morning of Monday, November 25th 2024. The 1-100 reverse split was announced on Thursday, November 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apollomics investors own include NVIDIA (NVDA), Cara Therapeutics (CARA), Akebia Therapeutics (AKBA), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Canoo (GOEV) and MSP Recovery (LIFW).

Company Calendar

Today
5/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APLM
Fax
N/A
Employees
45
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.22 million
Price / Cash Flow
N/A
Book Value
$47.51 per share
Price / Book
0.15

Miscellaneous

Free Float
N/A
Market Cap
$7.62 million
Optionable
Not Optionable
Beta
0.93
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:APLM) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners